報價延遲最少15分鐘:2026/05/15 12:05 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.685 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.55/0.09
|
|
企業價值
1.31B
|
| 資產負債 |
|
每股賬面淨值
2.32
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
788.37M
|
|
每股收益
2.45
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA. |
